Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
ALIM
$6.84
Alimera Sciences
$.11
1.63%
ALIM
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus: ($0.37)
Revenue: $15.17 Mil
Wednesday
Oct 26
7:30 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Wednesday, July 27, 2022
Alimera Sciences Announces Second Quarter 2022 Financial Results
What do you expect when ALIM reports earnings?
Beat
Meet
Miss
Where is ALIM's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
-
-
-
-
Support
-
-
-
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Peers
Vertex Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
Johnson & Johnson
Regeneron Pharmaceuticals
Ultragenyx Pharmaceutical
Eli Lilly
BioMarin Pharmaceutical
Pfizer
Array Technologies
Expectations
›
Alimera Sciences